Health care investor company Water Street Healthcare Partners reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) as well as the availability of the ready-to-use cardiovascular medication, eptifibatide.

The approval of eptifibatide marks the seventh drug product successfully developed by Water Street's company, Celerity Pharmaceuticals LLC.

In conjunction, the US Food and Drug Administration's (FDA) approval and launch of the ready-to-use cardiovascular medication, eptifibatide follows Celerity Pharmaceuticals LLC's strategic development partnership with a leading medical products company.

As part of the partnership, Celerity both funded and led the development and approval of eptifibatide through its strategic partnership with the medical products company. Following FDA approval of eptifibatide, Celerity transferred ownership to its partner, which is commercially launching the new product in the US.

This ready-to-use cardiovascular medicine is the first and only presentation of eptifibatide in a flexible container, concluded the companies.